Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwAL 2022 | Immunotherapeutics in AML

In this discussion, Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, and Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, discuss novel immunotherapeutic approaches being explored in acute myeloid leukemia (AML). This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.